Rutgers Cancer Institute of New Jersey

Recent papers from Rutgers Cancer Institute of New Jersey

1. The (amide-)N-methylnicotinamide is a microbe-derived NAD + precursor that drives gut stem cell renewalScience Advances · 2026
2. Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCLAmerican Journal of Hematology · 2026
3. HPV DNA integration is correlated with persistence or progression of cervical intraepithelial neoplasia 2 (CIN2)Gynecologic Oncology · 2026
4. Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticariaMedicinal Chemistry Research · 2026
5. Barriers to Breast Cancer Care: Patient Navigation Pilot Results From Mwanza, TanzaniaJCO Global Oncology · 2026
6. Raymond G. McCarthy: Architect of Alcohol Education in the Twentieth CenturyJournal of Studies on Alcohol and Drugs · 2026
7. Spatial mapping of state transitions at the tumor-stroma interface in bladder cancernpj Systems Biology and Applications · 2026
8. The Duffy-Null genotype and epithelial ovarian cancer survival in a cohort of Black womenGynecologic Oncology · 2026
9. “The significance of context”: Fit, friction, and function in the work lives of early career academics with ADHDPLoS ONE · 2026
10. KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
11. TEDEdb: A multicohort analysis and resource for transposable element differential expression in cancerProceedings of the National Academy of Sciences · 2026
12. Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma:Blood Advances · 2026
13. Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective studyEBioMedicine · 2026
14. Targeted radioligand therapy in oncology: clinical development across targets and platformsFrontiers in Oncology · 2026
15. Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI TherapyNew England Journal of Medicine · 2026
16. Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patientsCancer · 2026
17. Primary care physicians on caring for patients with complex comorbidities and history of breast cancerBMC Family Practice · 2026
18. COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
19. Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast CancerJAMA Oncology · 2026
20. CAR ‐ HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphomaBritish Journal of Haematology · 2026